A double-blind, placebo-controlled study to assess the mitochondria-targeted antioxidant MitoQ as a disease-modifying therapy in Parkinson's disease

Authors

  • Barry J. Snow MD,

    Corresponding author
    1. Neurology Department, Auckland Hospital, Auckland, New Zealand
    • Neurology Department, Auckland Hospital, Auckland, New Zealand
    Search for more papers by this author
    • Potential conflict of interest: KMT is CEO of Antipodean Pharmaceuticals. BJS, MPM, and RAJS are consultants and scientific advisors to Antipodean Pharmaceuticals. MPM and RAJS have a share of the ownership of IP being developed by Antipodean Pharmaceuticals.

  • Fiona L. Rolfe BSc,

    1. Antipodean Pharmaceuticals, Auckland, New Zealand
    Search for more papers by this author
  • Michelle M. Lockhart MM,

    1. Antipodean Pharmaceuticals, Auckland, New Zealand
    Search for more papers by this author
  • Christopher M. Frampton PhD,

    1. Department of Medicine, Christchurch School of Medicine and Health Sciences, Christchurch Hospital, Christchurch, New Zealand
    Search for more papers by this author
  • John D. O'Sullivan MD,

    1. Division of Medicine, Neurology Research Centre and University of Queensland Clinical School, Royal Brisbane & Women's Hospital, Brisbane, Australia
    Search for more papers by this author
  • Victor Fung PhD, FRACP,

    1. Department of Neurology, Westmead Hospital, Sydney Medical School, University of Sydney, Sydney, Australia
    Search for more papers by this author
  • Robin A.J. Smith PhD,

    1. Chemistry Department, University of Otago, Dunedin, New Zealand
    Search for more papers by this author
    • Potential conflict of interest: KMT is CEO of Antipodean Pharmaceuticals. BJS, MPM, and RAJS are consultants and scientific advisors to Antipodean Pharmaceuticals. MPM and RAJS have a share of the ownership of IP being developed by Antipodean Pharmaceuticals.

  • Michael P. Murphy PhD,

    1. Medical Research Council Mitochondrial Biology Unit, Cambridge, United Kingdom
    Search for more papers by this author
    • Potential conflict of interest: KMT is CEO of Antipodean Pharmaceuticals. BJS, MPM, and RAJS are consultants and scientific advisors to Antipodean Pharmaceuticals. MPM and RAJS have a share of the ownership of IP being developed by Antipodean Pharmaceuticals.

  • Kenneth M. Taylor PhD

    1. Antipodean Pharmaceuticals, Auckland, New Zealand
    Search for more papers by this author
    • Potential conflict of interest: KMT is CEO of Antipodean Pharmaceuticals. BJS, MPM, and RAJS are consultants and scientific advisors to Antipodean Pharmaceuticals. MPM and RAJS have a share of the ownership of IP being developed by Antipodean Pharmaceuticals.


Abstract

Multiple lines of evidence point to mitochondrial oxidative stress as a potential pathogenic cause for Parkinson's disease (PD). MitoQ is a powerful mitochondrial antioxidant. It is absorbed orally and concentrates within mitochondria where it has been shown to protect against oxidative damage. We enrolled 128 newly diagnosed untreated patients with PD in a double-blind study of two doses of MitoQ compared with placebo to explore the hypothesis that, over 12 months, MitoQ would slow the progression of PD as measured by clinical scores, particularly the Unified Parkinson Disease Rating Scale. We showed no difference between MitoQ and placebo on any measure of PD progression. MitoQ does not slow the progression of PD, and this finding should be taken into account when considering the oxidative stress hypothesis for the pathogenesis of PD. © 2010 Movement Disorder Society

Ancillary